<p>Macular dystrophies (MDs) are a group of inherited retinal disorders that cause significant visual loss, most often as a result of progressive macular atrophy. They are characterized by bilateral, relatively symmetrical macular abnormalities that significantly impair central visual function.</p>
<p>Stargardt disease, also known as Stargardt&rsquo;s macular dystrophy or juvenile macular degeneration, stands out as the most prevalent form of macular degeneration in children. Patients grappling with Stargardt disease encounter visual acuity loss, often manifesting in their first or second decades of life, attributed to the atrophy of the retinal pigment epithelium (RPE) and the progressive decline of functional photoreceptors. Stargardt disease invariably results in irreversible decreased vision in nearly all cases.</p>
<p>Stargardt is a genetic disorder. In its typical form (STGD1), it is caused by mutations involving the ABCA4 gene through autosomal recessive homozygous or compound heterozygous transmission. Additionally, autosomal dominant transmission (STGD4) is possible through heterozygous mutations in the PROM1 gene (4p).</p>
<p>Stargardt-like macular dystrophies (STGD3), associated with dominant mutations in the ELOVL4 gene (6q14.1), share clinical features with typical Stargardt disease (STGD2). STGD2 was later identified as the same gene as STGD3, leading to the discontinuation of the term STGD2 in 2005.</p>
<h2><strong>Stargardt Disease Epidemiological Segmentation</strong></h2>
<p>The Epidemiological Segmentation of Stargardt Disease in 7MM from 2020 to 2034 is segmented as:-</p>
<ul>
<li>Diagnosed prevalent cases</li>
<li>Region-specific cases</li>
<li>Onset-age specific cases</li>
<li>Type-specific cases</li>
<li>Symptom-specific cases</li>
<li>Total diagnosed cases</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/stargardt-disease-stgd-epidemiology-forecast"><span style="text-decoration: underline;"><strong>Stargardt Disease Epidemiology</strong></span></a></h2>
<ul>
<li>In the 7MM, there were approximately 53K diagnosed prevalent cases of Parkinson&rsquo;s disease.</li>
<li>In the United States, Parkinson&rsquo;s disease accounted for 43% of the total diagnosed prevalent cases, representing a significant portion of the 7MM.</li>
<li>Among the EU4 and the UK, 41% of Parkinson&rsquo;s disease cases were observed, making up a substantial share of the diagnosed cases.</li>
<li>In Japan, 16% of the total diagnosed cases of Parkinson&rsquo;s disease were reported.</li>
<li>The highest onset age-specific cases of Parkinson&rsquo;s disease in the United States were among individuals under 20 years old.</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/stargardt-disease-stgd-market"><span style="text-decoration: underline;"><strong>Stargardt Disease Market</strong></span></a></h2>
<p>The Stargardt Disease market size in the 7MM was&nbsp; ~USD 27 Million in 2023.</p>
<h2>Stargardt Disease Market Drivers:</h2>
<ul>
<li>Advancements in gene therapy offer potential disease-modifying treatments.</li>
<li>Increased awareness leads to earlier diagnosis and better management.</li>
<li>Rising investment in rare disease research accelerates treatment development.</li>
<li>Innovative drug delivery systems enhance treatment efficacy and options.</li>
</ul>
<h2>Stargardt Disease Market Barriers:</h2>
<ul>
<li>Limited effective treatment options for Stargardt disease.</li>
<li>High costs of novel therapies restrict accessibility.</li>
<li>Challenges in early diagnosis delay treatment and management.</li>
<li>Complex regulatory approval processes slow therapy availability.</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/stargardt-disease-stgd-pipeline-insight"><span style="text-decoration: underline;"><strong>Stargardt Disease Emerging Drugs</strong></span></a></h2>
<ul>
<li>&nbsp;ALK-001 (gildeuretinol)</li>
<li>Tinlarebant (LSB-008)</li>
<li>IZERVAY (avacincaptad pegol)</li>
<li>Emixustat</li>
<li>MCO-010 (Gene Therapy)&nbsp;</li>
</ul>
<p>And others.&nbsp;</p>
<h2><strong>Stargardt Disease Key Players</strong></h2>
<ul>
<li>Kubota Pharmaceuticals</li>
<li>Nanoscope Therapeutics</li>
<li>Alkeus Pharmaceuticals</li>
<li>Belite Bio</li>
<li>Astellas Pharma</li>
</ul>
<p>And others.</p>

Stargardt Disease Market

Stargardt Disease Market Infograhic

Stargardt Disease Market Infographic

Stargardt Disease Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.